ARCADIA - Atrial Cardiopathy and Antithrombotic Drugs in Prevention after Cryptogenic Stroke Trial
ARTESIA - Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation
ASSERT - Atrial Fibrillation Reduction Atrial Pacing Trial
ATTICUS - Apixaban for Treatment of Embolic Stroke of Undetermined Source
CLOSE - Patent Foramen Ovale Closure or Anticoagulants versus Antiplatelet Therapy to Prevent Stroke Recurrence
CRYSTAL-AF - The Cryptogenic Stroke and Underlying AF
DEFENSE-PFO - Device Closure Versus Medical Therapy for Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale
EMBRACE-trial - the 30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation after a Cerebral Ischemic Event
FIND AF RANDOMISED - Finding atrial fibrillation in stroke patients: Randomized evaluation of enhanced and prolonged Holter monitoring
MOST-Cancer - Mechanisms Of ischemic STroke in Cancer patients
NAVIGATE ESUS - New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source
OXVASC - OXford VASCular study
PICSS - Patent Foramen Ovale in Cryptogenic Stroke Study
REDUCE - GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients
RESPECT - Randomized Evaluation of Recurrent Stroke Comparing PFO Closure to Established Current Standard of Care Treatment
RE-SPECT ESUS - Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the Efficacy and safety of the oral Thrombin inhibitor dabigatran etexilate vs acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source
WARSS - Warfarin-Aspirin Recurrent Stroke Study